Autologous stem cell transplantation for stiff person syndrome: two cases from the Ottawa blood and marrow transplant program

JAMA Neurol. 2014 Oct;71(10):1296-9. doi: 10.1001/jamaneurol.2014.1297.

Abstract

Importance: Stiff person syndrome (SPS) is a rare neurological disease causing significant functional disability for patients and presenting a therapeutic challenge for clinicians. Autologous hematopoietic stem cell transplantation (auto-HSCT) has been used successfully to remit autoimmune-mediated neurological diseases. We report 2 cases of severe SPS treated with auto-HSCT, a novel therapy for this disease.

Observations: Two anti-glutamic acid decarboxylase antibody-positive patients with SPS had an autologous hematopoietic stem cell graft collected and stored. Subsequently, the patients underwent auto-HSCT. Both patients achieved clinical remission with sustained, marked improvement in symptoms and a return to premorbid functioning, now more than 2.5 and 4.5 years after the procedure.

Conclusions and relevance: Stiff person syndrome represents a novel indication for auto-HSCT. The resolution of clinical manifestations of SPS despite the persistence of anti-glutamic acid decarboxylase antibodies following auto-HSCT suggests that the antibody does not play a direct role in pathogenesis of SPS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Middle Aged
  • Severity of Illness Index
  • Stiff-Person Syndrome / immunology
  • Stiff-Person Syndrome / therapy*
  • Transplantation, Autologous
  • Treatment Outcome